Lantheus Holdings, Inc. (LNTH) stock
LNTHNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3010% above fair value
$101.25−0.35 (-0.34%)
Close on Nov 12, 2026Market cap $6.61BP/E 25.0Yield –
Lantheus EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Lantheus's EPS for the twelve months ending Sep 30, 2026 was $4.05, up 69.5% year over year. For fiscal 2025 it was $3.41, down 21.8% from the year before. The highest annual figure on record is $4.65 in fiscal 2023.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.41 | -21.8% |
| FY2024 | Dec 31, 2024 | $4.36 | -6.2% |
| FY2023 | Dec 31, 2023 | $4.65 | +1062.5% |
| FY2022 | Dec 31, 2022 | $0.40 | – |
| FY2021 | Dec 31, 2021 | -$1.06 | – |
| FY2020 | Dec 31, 2020 | -$0.25 | -131.6% |
| FY2019 | Dec 31, 2019 | $0.79 | -23.3% |
| FY2018 | Dec 31, 2018 | $1.03 | -67.5% |
| FY2017 | Dec 31, 2017 | $3.17 | +286.6% |
| FY2016 | Dec 31, 2016 | $0.82 | – |
| FY2015 | Dec 31, 2015 | -$0.60 | – |
| FY2014 | Dec 31, 2014 | -$0.20 | – |
| FY2013 | Dec 31, 2013 | -$3.42 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $0.33 | -19.5% |
| Q2 FY2026 | Jun 30, 2026 | $1.11 | -0.9% |
| Q1 FY2026 | Mar 31, 2026 | $1.80 | +76.5% |
| Q4 FY2025 | Dec 31, 2025 | $0.81 | – |
| Q3 FY2025 | Sep 30, 2025 | $0.41 | -77.1% |
| Q2 FY2025 | Jun 30, 2025 | $1.12 | +27.3% |
| Q1 FY2025 | Mar 31, 2025 | $1.02 | -45.5% |
| Q4 FY2024 | Dec 31, 2024 | -$0.16 | -110.9% |
| Q3 FY2024 | Sep 30, 2024 | $1.79 | -4.8% |
| Q2 FY2024 | Jun 30, 2024 | $0.88 | -33.8% |
| Q1 FY2024 | Mar 31, 2024 | $1.87 | – |
| Q4 FY2023 | Dec 31, 2023 | $1.47 | – |
| Q3 FY2023 | Sep 30, 2023 | $1.88 | +118.6% |
| Q2 FY2023 | Jun 30, 2023 | $1.33 | +118.0% |
| Q1 FY2023 | Mar 31, 2023 | -$0.04 | -106.6% |
| Q4 FY2022 | Dec 31, 2022 | -$1.69 | – |
| Q3 FY2022 | Sep 30, 2022 | $0.86 | – |
| Q2 FY2022 | Jun 30, 2022 | $0.61 | – |
| Q1 FY2022 | Mar 31, 2022 | $0.61 | +369.2% |
| Q4 FY2021 | Dec 31, 2021 | -$0.59 | – |
| Q3 FY2021 | Sep 30, 2021 | -$0.20 | – |
| Q2 FY2021 | Jun 30, 2021 | -$0.39 | – |
| Q1 FY2021 | Mar 31, 2021 | $0.13 | +62.5% |
| Q4 FY2020 | Dec 31, 2020 | -$0.05 | -119.2% |
| Q3 FY2020 | Sep 30, 2020 | -$0.10 | -183.3% |
| Q2 FY2020 | Jun 30, 2020 | -$0.16 | -200.0% |
| Q1 FY2020 | Mar 31, 2020 | $0.08 | -68.0% |
| Q4 FY2019 | Dec 31, 2019 | $0.26 | -23.5% |
| Q3 FY2019 | Sep 30, 2019 | $0.12 | -50.0% |
| Q2 FY2019 | Jun 30, 2019 | $0.16 | -36.0% |
| Q1 FY2019 | Mar 31, 2019 | $0.25 | +19.0% |
| Q4 FY2018 | Dec 31, 2018 | $0.34 | -86.2% |
| Q3 FY2018 | Sep 30, 2018 | $0.24 | +9.1% |
| Q2 FY2018 | Jun 30, 2018 | $0.25 | -28.6% |
| Q1 FY2018 | Mar 31, 2018 | $0.21 | +90.9% |
| Q4 FY2017 | Dec 31, 2017 | $2.47 | +1800.0% |
| Q3 FY2017 | Sep 30, 2017 | $0.22 | – |
| Q2 FY2017 | Jun 30, 2017 | $0.35 | – |
| Q1 FY2017 | Mar 31, 2017 | $0.11 | – |
| Q4 FY2016 | Dec 31, 2016 | $0.13 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?